EAD (TTM)

EAD/share (TTM)

EAD (Quarter)

EAD/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/EAD

Based in Westbury, NY, ACRES Commercial Realty Corp is a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and other commercial real estate-related debt investments. The Company is externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., a private commercial real estate lender exclusively dedicated to nationwide middle market CRE lending with a focus on multifamily, student housing, hospitality, office, industrial and other asset types in top US markets.

ACRES Commercial Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q4

Years since IPO: 15/15,
EAD Growth: 6/15,
EAD/share Growth: 11/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2026 Q1

Years since IPO: 15/15,
EAD Growth: 8/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2026 Q2

Years since IPO: 15/15,
EAD Growth: 3/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2026 Q3

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 12/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's EAD

EAD Growth

Assessment of recent increases in EAD per share, indicating profitability

EAD/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable 100% (3 of 3) of extrarenal lupus patients treated with FT819 without the use of conditioning chemotherapy experienced measurable responses with two patients achieving the Definition of Remission in Systemic Lupus Erythematosus (DORIS) and the third achieving Lupus Low Disease Activity State (LLDAS) First patient treated with two doses of FT819 achieved a significant reduction of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) by 8 points at Month 1, achieving LLDAS by Month 2, which was sustained at Month 3 New preclinical data show FT839 eliminates a broad spectrum of activated immune cells in models of rheumatoid arthritis supporting immune cell reset in multicellular disease; COMPLETE™ Phase 1/2 basket trial open for enrollment SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that updated clinical data for FT819, together with translational and patient-perspective data, as well as preclinical data for FT839, are being presented in four presentations at the American College of Rheumatology (ACR) Convergence 2026, held November 6–11 in Orlando, Florida. "Our recent clinical data presented at ACR continues to show that FT819 can be delivered in a safe and effective manner that fits into routine rheumatology care," said Bob Valamehr, Ph.D.

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis, supporting the Company's planned Phase 2 study in patients with gout.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout

BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of dapirolizumab pegol (DZP), an investigational biologic for people living with systemic lupus erythematosus (SLE). The data are being presented across five posters at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, in Orlando, Florida, November 6-11.

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

SYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced positive data from its Phase I study of IMP761, its first-in-class LAG-3 agonist antibody, from a late-breaking abstract at ACR Convergence 2026 in Orlando, Florida. ACR Convergence is the annual scientific meeting of the American College of Rheumatology.

IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses

Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026

100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases

ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity November 7, 2026, 10:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis will be featured in a late-breaking oral presentation (#LB24) at the American College of Rheumatology (ACR) Convergence 2026 on November 11, 2026, from 9:15-9:30 a.m. ET. Combined IMNM and DM population: Primary and key secondary endpoints met The study met its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patient population, demonstrating that patients treated with efgartigimod achieved a statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (p=0.0011; 48.0 vs 32.6).

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

ACRES Commercial Realty NYSE: ACR reported a third-quarter loss as it absorbed transaction-related charges following its merger and internalization, while executives outlined plans to grow earnings through investment management and insurance.

What ACRES Commercial Realty (ACR) Said on Its Q3 Earnings Call

Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no knee pain at the end of the trials Detailed Phase 3b TOGETHER-PsA data showed positive results across disease activity, patient-reported and metabolic outcomes at one year for Taltz and Zepbound vs. Taltz alone in adults with psoriatic arthritis and obesity INDIANAPOLIS, Nov. 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new clinical and real-world research in people with knee osteoarthritis pain and obesity and those with psoriatic arthritis and obesity at the American College of Rheumatology (ACR) Convergence 2026, taking place Nov. 6-11 in Orlando.

Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity

UNIONDALE, N.Y., Nov. 4, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp.

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2026

ACRES Commercial Realty (NYSE: ACR - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.15 per share and revenue of $21.23 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings

ACRES Commercial Realty (ACR) Set to Announce Quarterly Earnings on Wednesday

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA publishes the issuer rating of BB, senior secured debt rating of BBB-, and preferred stock rating of BB- for ACRES Commercial Realty Corp. (NYSE: ACR, “ACRES”, or “the company”). The Outlook for the ratings is Stable. On August 5, 2026, these ratings were assigned on an unpublished basis. Key Credit Considerations On August 6, 2026, ACR, a real estate investment trust, acquired ACRES Capital Corp. (“ACC”), a commercial real estate (“CRE”) investment manager found.

KBRA Publishes Ratings for ACRES Commercial Realty Corp.

Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable clinical activity, including confirmed complete and partial responses (RECIST 1.1) with ACR-2316 monotherapy in heavily pretreated, AP3-predicted tumor types, including endometrial and lung cancers Activity in K-Ras pathway mutated cancers and reported synthetic lethality for WEE1 inhibition in K-Ras gain-of-function and TP53 loss-of-function tumors support expansion of study to include pancreatic ductal adenocarcinoma (PDAC) Favorable, differentiated safety profile to date, primarily limited to transient, asymptomatic neutropenia Strong synergistic activity observed with immune checkpoint inhibitors (ICI) and topoisomerase 1 (TOPO1) inhibitors support potential for broader frontline combination strategies across solid tumors WATERTOWN, Mass.

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium

UNIONDALE, N.Y., Oct. 21, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company" or "ACRES") announced today that it will release its results for the third quarter 2026 on Wednesday, November 4, 2026, after the market closes.

ACRES Commercial Realty Corp. to Report Results for Third Quarter 2026

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors IND-enabling studies ongoing with IND submission on track for first half of 2027 WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the advancement of ACR-7280, a potential first-in-class, oral CDK11 inhibitor, as its next development candidate generated from its AI-enabled AP3 innovation platform.

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), a population similar to that being studied in the Phase 3 registrational trial Live webcast on Monday, November 9, 2026 at 8:15 am EST to review Artiva's presentations, including an in-depth analysis of data from at least 10 patients with refractory RA who have at least six months of follow-up and would meet key eligibility criteria for the Phase 3 registrational trial SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK® program and a registry analysis of the high unmet medical need in refractory RA. Artiva will host a live webcast on Monday, November 9, 2026, at 8:15 am EST to review its ACR presentations and updated clinical data from at least 20 patients with refractory RA who have at least six months of follow-up.

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

UNIONDALE, N.Y., Sept. 29, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $5.0 million of the outstanding shares of its common stock.

ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program

On September 25, 2026, ACRES Commercial Realty Corp (ACR) shares fell 4.4%, closing at $10.48. This recent decline has contributed to a staggering year-to-date

ACRES Commercial Realty Corp (ACR) Stock Down 4.4% -- Now Undervalued? GF Score: 57/100

SAN JOSE, Calif--(BUSINESS WIRE)--TiVo Ads, a leader in advanced TV data and advertising solutions, today launched an enhanced U.S. TV Viewership Data offering, combining its deterministic set-top box (STB) data with automatic content recognition (ACR) data in a single, session-level data feed.Building on more than 15 years of experience in TV data licensing, TiVo Ads provides data, measurement and analytics partners with a scaled and diversified footprint spanning millions of combined STB and A.

TiVo Ads Launches Enhanced U.S. TV Viewership Data Offering, Unifying STB and ACR Data in a Single Feed

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

UNIONDALE, N.Y., Sept. 16, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

UPDATED SAFETY DATA OF 36 PATIENTS TREATED WITH FT819 ACROSS THREE REGIMENS AND FOUR AUTOIMMUNE DISEASE INDICATIONS WITH NO DOSE-LIMITING TOXICITIES CONTINUES TO BE FAVORABLE 100% (3 OF 3) OF EXTRARENAL LUPUS PATIENTS TREATED WITH FT819 WITHOUT THE USE OF CONDITIONING CHEMOTHERAPY EXPERIENCED MEASURABLE RESPONSES WITH TWO PATIENTS ACHIEVING THE DEFINITION OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS (DORIS) AND THE THIRD ACHIEVING LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) FIRST PATIENT TREATED WITH TWO DOSES OF FT819 ACHIEVED A SIGNIFICANT REDUCTION OF SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI-2K) BY 8 POINTS AT MONTH 1, ACHIEVING LLDAS BY MONTH 2, WHICH WAS SUSTAINED AT MONTH 3 NEW PRECLINICAL DATA SHOW FT839 ELIMINATES A BROAD SPECTRUM OF ACTIVATED IMMUNE CELLS IN MODELS OF RHEUMATOID ARTHRITIS SUPPORTING IMMUNE CELL RESET IN MULTICELLULAR DISEASE; COMPLETE PHASE 1/2 BASKET TRIAL OPEN FOR ENROLLMENT SAN DIEGO, NOV. 10, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE AND BROADLY ACCESSIBLE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT UPDATED CLINICAL DATA FOR FT819, TOGETHER WITH TRANSLATIONAL AND PATIENT-PERSPECTIVE DATA, AS WELL AS PRECLINICAL DATA FOR FT839, ARE BEING PRESENTED IN FOUR PRESENTATIONS AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2026, HELD NOVEMBER 611 IN ORLANDO, FLORIDA. "OUR RECENT CLINICAL DATA PRESENTED AT ACR CONTINUES TO SHOW THAT FT819 CAN BE DELIVERED IN A SAFE AND EFFECTIVE MANNER THAT FITS INTO ROUTINE RHEUMATOLOGY CARE," SAID BOB VALAMEHR, PH.D.

FATE THERAPEUTICS PRESENTS NEW FT819 DATA AT ACR CONVERGENCE 2026 HIGHLIGHTING MEANINGFUL CLINICAL RESPONSES IN LUPUS WITHOUT THE USE OF CONDITIONING CHEMOTHERAPY

NEK7-DIRECTED MOLECULAR GLUE DEGRADER INHIBITED NLRP3 INFLAMMASOME ACTIVATION IN HUMAN EXPERIMENTAL SYSTEMS AND DEMONSTRATED ANTI-INFLAMMATORY ACTIVITY IN A RABBIT MODEL OF GOUTY ARTHRITIS GEMINI-1, A PHASE 2 STUDY OF MRT-8102 IN PATIENTS WITH GOUT, IS EXPECTED TO INITIATE IN Q4 2026, WITH INITIAL DATA EXPECTED IN H2 2027 POSTER PRESENTATION ON NOVEMBER 9, 2026, AT 10:30 A.M. ET BOSTON, NOV. 09, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE PRESENTATION OF PRECLINICAL DATA SHOWING THAT MRT-8102, A NEK7-DIRECTED MGD, INHIBITED NLRP3 INFLAMMASOME ACTIVITY IN HUMAN EXPERIMENTAL SYSTEMS AND REDUCED INFLAMMATION IN A RABBIT MODEL OF GOUTY ARTHRITIS, SUPPORTING THE COMPANY'S PLANNED PHASE 2 STUDY IN PATIENTS WITH GOUT.

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT ACR CONVERGENCE 2026 ON THE POTENTIAL OF MRT-8102 IN GOUT

BRUSSELS AND CAMBRIDGE, MASS., NOV. 09, 2026 (GLOBE NEWSWIRE) -- UCB (EURONEXT BRUSSELS: UCB) AND BIOGEN INC. (NASDAQ: BIIB) TODAY ANNOUNCED FURTHER DATA CHARACTERIZING THE CLINICAL PROFILE OF DAPIROLIZUMAB PEGOL (DZP), AN INVESTIGATIONAL BIOLOGIC FOR PEOPLE LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). THE DATA ARE BEING PRESENTED ACROSS FIVE POSTERS AT ACR CONVERGENCE 2026, THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, IN ORLANDO, FLORIDA, NOVEMBER 6-11.

ACR 2026: DAPIROLIZUMAB PEGOL ASSOCIATED WITH GREATER TREATMENT RESPONSE RATES VERSUS PLACEBO IN SLE USING NOVEL TREATMENT RESPONSE MEASURE

SYDNEY, AUSTRALIA, NOV. 08, 2026 (GLOBE NEWSWIRE) -- IMMUTEP LIMITED (ASX: IMM; NASDAQ: IMMP) ("IMMUTEP" OR "THE COMPANY"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TARGETING CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED POSITIVE DATA FROM ITS PHASE I STUDY OF IMP761, ITS FIRST-IN-CLASS LAG-3 AGONIST ANTIBODY, FROM A LATE-BREAKING ABSTRACT AT ACR CONVERGENCE 2026 IN ORLANDO, FLORIDA. ACR CONVERGENCE IS THE ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY.

IMP761 LATE-BREAKING ABSTRACT AT ACR CONVERGENCE 2026 HIGHLIGHTS STATISTICALLY SIGNIFICANT & EXPOSURE-DEPENDENT INHIBITION OF T-CELL-DRIVEN IMMUNE RESPONSES

CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE ACTIVITY AMONG 8 OF 9 EVALUABLE PATIENTS, INCLUDING RAPID AND MARKED REDUCTIONS IN PROTEINURIA WITH COMPLETE RENAL RESPONSES

VELINOTAMIG, A BCMAXCD3 T CELL ENGAGER, ACHIEVES COMPLETE RENAL RESPONSES AND SIGNIFICANTLY REDUCES DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS IN DATA PRESENTED AT ACR CONVERGENCE 2026

100% (6 OF 6) OF DERMATOMYOSITIS PATIENTS MAINTAINED IMMUNOMODULATOR-FREE, MODERATE-TO-MAJOR TIS RESPONSES THROUGH ONE YEAR, WITH MOST PATIENTS ALSO FREE OF STEROIDS

CABALETTA BIO PRESENTS NEW RESE-CEL PHASE 1/2 CLINICAL DATA AT ACR CONVERGENCE 2026 FEATURING IMMUNOMODULATOR-FREE DURABILITY AND FAVORABLE BENEFIT-RISK PROFILE ACROSS AUTOIMMUNE DISEASES

ALKIVIA MET ITS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE COMBINED IMNM AND DM POPULATION FIRST PHASE 3 STUDY TO DEMONSTRATE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFIT IN IMNM, AN AUTOIMMUNE MYOSITIS SUBTYPE WITH NO APPROVED THERAPIES CONSISTENT, CLINICALLY MEANINGFUL TREATMENT EFFECT IN DM, DEMONSTRATING IMPROVEMENTS IN MUSCLE STRENGTH AND SKIN DISEASE ACTIVITY NOVEMBER 7, 2026, 10:00 AM ET AMSTERDAM, THE NETHERLANDS  ARGENX SE (EURONEXT & NASDAQ: ARGX), THE IMMUNOLOGY INNOVATION COMPANY, TODAY ANNOUNCED THAT DATA FROM THE PHASE 3 ALKIVIA STUDY DEMONSTRATING RAPID AND SUSTAINED IMPROVEMENT WITH VYVGART  HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) IN PATIENTS WITH AUTOIMMUNE MYOSITIS WILL BE FEATURED IN A LATE-BREAKING ORAL PRESENTATION (#LB24) AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2026 ON NOVEMBER 11, 2026, FROM 9:15-9:30 A.M. ET. COMBINED IMNM AND DM POPULATION: PRIMARY AND KEY SECONDARY ENDPOINTS MET THE STUDY MET ITS PRIMARY ENDPOINT IN THE COMBINED IMMUNE-MEDIATED NECROTIZING MYOPATHY (IMNM) AND DERMATOMYOSITIS (DM) PATIENT POPULATION, DEMONSTRATING THAT PATIENTS TREATED WITH EFGARTIGIMOD ACHIEVED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL 15.4-POINT GREATER IMPROVEMENT IN MEAN TOTAL IMPROVEMENT SCORE (TIS) AT WEEK 52 VERSUS PLACEBO (P=0.0011; 48.0 VS 32.6).

ARGENX PRESENTS PHASE 3 ALKIVIA DATA AT ACR CONVERGENCE 2026 SHOWING RAPID AND SUSTAINED IMPROVEMENT WITH EFGARTIGIMOD IN AUTOIMMUNE MYOSITIS

ASSET ACQUISITION ESTABLISHES IMMUNOLOGY AND INFLAMMATION (I&I) AS A STRATEGIC PILLAR ALONGSIDE ONCOLOGY, EXTENDING THE COMPANY INTO AUTOIMMUNE DISEASE

ACRIVON EXPANDS INTO IMMUNOLOGY AND INFLAMMATION WITH ACQUISITION OF PHASE 2-READY DIFFERENTIATED, ORAL JAK1 INHIBITOR ACR-525, AND PKC INHIBITOR PRECLINICAL PROGRAM FROM AQILION AB

PIVOTAL RESULTS FROM THE PHASE 3 TRIUMPH-1 AND TRIUMPH-4 TRIALS SHOWED RETATRUTIDE DELIVERED SUBSTANTIAL REDUCTIONS IN KNEE PAIN AND WEIGHT IN ADULTS WITH KNEE OSTEOARTHRITIS AND OBESITY, WITH SOME EXPERIENCING NO KNEE PAIN AT THE END OF THE TRIALS DETAILED PHASE 3B TOGETHER-PSA DATA SHOWED POSITIVE RESULTS ACROSS DISEASE ACTIVITY, PATIENT-REPORTED AND METABOLIC OUTCOMES AT ONE YEAR FOR TALTZ AND ZEPBOUND VS. TALTZ ALONE IN ADULTS WITH PSORIATIC ARTHRITIS AND OBESITY INDIANAPOLIS, NOV. 5, 2026 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) WILL PRESENT NEW CLINICAL AND REAL-WORLD RESEARCH IN PEOPLE WITH KNEE OSTEOARTHRITIS PAIN AND OBESITY AND THOSE WITH PSORIATIC ARTHRITIS AND OBESITY AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2026, TAKING PLACE NOV. 6-11 IN ORLANDO.

LILLY TO SHOWCASE NEW RETATRUTIDE, TALTZ (IXEKIZUMAB) AND ZEPBOUND (TIRZEPATIDE) DATA AT ACR CONVERGENCE 2026, ADVANCING SCIENCE AT THE INTERSECTION OF RHEUMATOLOGIC CONDITIONS AND OBESITY

UNIONDALE, N.Y., NOV. 4, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP.

NEW YORK--(BUSINESS WIRE)-- #CREDITRATINGAGENCY--KBRA PUBLISHES THE ISSUER RATING OF BB, SENIOR SECURED DEBT RATING OF BBB-, AND PREFERRED STOCK RATING OF BB- FOR ACRES COMMERCIAL REALTY CORP. (NYSE: ACR, ACRES, OR THE COMPANY). THE OUTLOOK FOR THE RATINGS IS STABLE. ON AUGUST 5, 2026, THESE RATINGS WERE ASSIGNED ON AN UNPUBLISHED BASIS. KEY CREDIT CONSIDERATIONS ON AUGUST 6, 2026, ACR, A REAL ESTATE INVESTMENT TRUST, ACQUIRED ACRES CAPITAL CORP. (ACC), A COMMERCIAL REAL ESTATE (CRE) INVESTMENT MANAGER FOUND.

KBRA PUBLISHES RATINGS FOR ACRES COMMERCIAL REALTY CORP.

TIMOTHY A. YAP, MBBS, PH.D., FRCP, OF THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER TO PRESENT RESULTS FROM THE DOSE ESCALATION PHASE OF THE ACR-2316 PHASE 1/2 TRIAL ON NOVEMBER 20, 2026 DURABLE CLINICAL ACTIVITY, INCLUDING CONFIRMED COMPLETE AND PARTIAL RESPONSES (RECIST 1.1) WITH ACR-2316 MONOTHERAPY IN HEAVILY PRETREATED, AP3-PREDICTED TUMOR TYPES, INCLUDING ENDOMETRIAL AND LUNG CANCERS ACTIVITY IN K-RAS PATHWAY MUTATED CANCERS AND REPORTED SYNTHETIC LETHALITY FOR WEE1 INHIBITION IN K-RAS GAIN-OF-FUNCTION AND TP53 LOSS-OF-FUNCTION TUMORS SUPPORT EXPANSION OF STUDY TO INCLUDE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) FAVORABLE, DIFFERENTIATED SAFETY PROFILE TO DATE, PRIMARILY LIMITED TO TRANSIENT, ASYMPTOMATIC NEUTROPENIA STRONG SYNERGISTIC ACTIVITY OBSERVED WITH IMMUNE CHECKPOINT INHIBITORS (ICI) AND TOPOISOMERASE 1 (TOPO1) INHIBITORS SUPPORT POTENTIAL FOR BROADER FRONTLINE COMBINATION STRATEGIES ACROSS SOLID TUMORS WATERTOWN, MASS.

ACRIVON ANNOUNCES LATE-BREAKING ORAL PLENARY PRESENTATION OF EARLY PHASE 1/2 CLINICAL RESULTS IN AP3-PREDICTED TUMORS FOR ITS FIRST-IN-CLASS WEE1/PKMYT1 INHIBITOR ACR-2316 AT THE 38TH EORTC-NCI-AACR SYMPOSIUM

UNIONDALE, N.Y., OCT. 21, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) (THE "COMPANY" OR "ACRES") ANNOUNCED TODAY THAT IT WILL RELEASE ITS RESULTS FOR THE THIRD QUARTER 2026 ON WEDNESDAY, NOVEMBER 4, 2026, AFTER THE MARKET CLOSES.

ACRES COMMERCIAL REALTY CORP. TO REPORT RESULTS FOR THIRD QUARTER 2026

ACR-7280 DEMONSTRATED COMPLETE TUMOR REGRESSION IN AGGRESSIVE AML XENOGRAFT MODELS PRIORITIZED AMONG MULTIPLE AP3-DISCOVERED, HIGHLY SELECTIVE CDK11 INHIBITOR CANDIDATES BASED ON POTENT SINGLE AGENT ACTIVITY AND STRONG SYNERGY WITH BCL-2 AND MENIN INHIBITORS IND-ENABLING STUDIES ONGOING WITH IND SUBMISSION ON TRACK FOR FIRST HALF OF 2027 WATERTOWN, MASS., OCT. 20, 2026 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (ACRIVON OR ACRIVON THERAPEUTICS) (NASDAQ: ACRV), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING PRECISION MEDICINES UTILIZING ITS PROPRIETARY GENERATIVE PHOSPHOPROTEOMICS AP3 (ACRIVON PREDICTIVE PRECISION PROTEOMICS) PLATFORM DEPLOYED FOR RATIONAL DRUG DESIGN AND PREDICTIVE CLINICAL DEVELOPMENT, TODAY ANNOUNCED THE ADVANCEMENT OF ACR-7280, A POTENTIAL FIRST-IN-CLASS, ORAL CDK11 INHIBITOR, AS ITS NEXT DEVELOPMENT CANDIDATE GENERATED FROM ITS AI-ENABLED AP3 INNOVATION PLATFORM.

ACRIVON ADVANCES ACR-7280, AN OPTIMIZED, AP3-ENABLED, POTENTIAL FIRST-IN-CLASS, ORAL CDK11 INHIBITOR TOWARD IND FILING IN FIRST HALF OF 2027

ZUG, SWITZERLAND AND BOSTON, OCT. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS (NASDAQ: CRSP), TODAY ANNOUNCED THAT A POSTER PRESENTATION HIGHLIGHTING THE COMPANY'S PHASE 1 CLINICAL DATA OF ITS INVESTIGATIONAL CRISPR/CAS9 GENE-EDITED ALLOGENEIC CAR T CELL THERAPY, ZUGOCABTAGENE GELEUCEL (ZUGO-CEL) TARGETING CD19 FOR AUTOIMMUNE DISEASE, WILL BE PRESENTED AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2026.

CRISPR THERAPEUTICS TO PRESENT CLINICAL DATA ON ZUGOCABTAGENE GELEUCEL (ZUGO-CEL) IN AUTOIMMUNE DISEASE AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2026

ORAL PRESENTATION HIGHLIGHTING UPDATED CLINICAL DATA FROM AT LEAST 20 PATIENTS WITH REFRACTORY RHEUMATOID ARTHRITIS (RA), 11 PATIENTS WITH SJGREN DISEASE (SJD) AND AT LEAST FIVE PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) TREATED WITH ALLONK PLUS RITUXIMAB IN THE ONGOING PHASE 2A BASKET TRIAL, ALL WITH AT LEAST SIX MONTHS OF FOLLOW-UP POSTER PRESENTATION HIGHLIGHTING DEEP, CONSISTENT B-CELL DEPLETION COMPARABLE TO THAT OBSERVED WITH CD19 CAR T-CELL THERAPIES AND A FAVORABLE TOLERABILITY PROFILE ACROSS IMMUNE-MEDIATED DISEASES POSTER PRESENTATION CHARACTERIZING THE HIGH UNMET MEDICAL NEED AND LOW CLINICAL RESPONSE RATES AMONG PATIENTS WITH REFRACTORY RA FOLLOWING AN INADEQUATE RESPONSE TO AT LEAST TWO DISTINCT CLASSES OF BIOLOGIC OR TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (B/TSDMARDS), A POPULATION SIMILAR TO THAT BEING STUDIED IN THE PHASE 3 REGISTRATIONAL TRIAL LIVE WEBCAST ON MONDAY, NOVEMBER 9, 2026 AT 8:15 AM EST TO REVIEW ARTIVA'S PRESENTATIONS, INCLUDING AN IN-DEPTH ANALYSIS OF DATA FROM AT LEAST 10 PATIENTS WITH REFRACTORY RA WHO HAVE AT LEAST SIX MONTHS OF FOLLOW-UP AND WOULD MEET KEY ELIGIBILITY CRITERIA FOR THE PHASE 3 REGISTRATIONAL TRIAL SAN DIEGO, OCT. 02, 2026 (GLOBE NEWSWIRE) -- ARTIVA BIOTHERAPEUTICS, INC. (NASDAQ: ARTV) (ARTIVA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WHOSE MISSION IS TO DEVELOP EFFECTIVE, SAFE AND ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH DEBILITATING AUTOIMMUNE DISEASES, TODAY ANNOUNCED ONE ORAL AND TWO POSTER PRESENTATIONS AT ACR CONVERGENCE 2026 FEATURING UPDATED DATA FROM ITS ALLONK PROGRAM AND A REGISTRY ANALYSIS OF THE HIGH UNMET MEDICAL NEED IN REFRACTORY RA. ARTIVA WILL HOST A LIVE WEBCAST ON MONDAY, NOVEMBER 9, 2026, AT 8:15 AM EST TO REVIEW ITS ACR PRESENTATIONS AND UPDATED CLINICAL DATA FROM AT LEAST 20 PATIENTS WITH REFRACTORY RA WHO HAVE AT LEAST SIX MONTHS OF FOLLOW-UP.

ARTIVA BIOTHERAPEUTICS ANNOUNCES MULTIPLE ALLONK DATA PRESENTATIONS AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2026

UNIONDALE, N.Y., SEPT. 29, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE:ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS (THE "BOARD") AUTHORIZED AND APPROVED THE CONTINUED USE OF ITS EXISTING SHARE REPURCHASE PROGRAM TO REPURCHASE AN ADDITIONAL $5.0 MILLION OF THE OUTSTANDING SHARES OF ITS COMMON STOCK.

ACRES COMMERCIAL REALTY CORP. REAUTHORIZES AN ADDITIONAL $5 MILLION SHARE REPURCHASE PROGRAM

SAN JOSE, CALIF--(BUSINESS WIRE)--TIVO ADS, A LEADER IN ADVANCED TV DATA AND ADVERTISING SOLUTIONS, TODAY LAUNCHED AN ENHANCED U.S. TV VIEWERSHIP DATA OFFERING, COMBINING ITS DETERMINISTIC SET-TOP BOX (STB) DATA WITH AUTOMATIC CONTENT RECOGNITION (ACR) DATA IN A SINGLE, SESSION-LEVEL DATA FEED.BUILDING ON MORE THAN 15 YEARS OF EXPERIENCE IN TV DATA LICENSING, TIVO ADS PROVIDES DATA, MEASUREMENT AND ANALYTICS PARTNERS WITH A SCALED AND DIVERSIFIED FOOTPRINT SPANNING MILLIONS OF COMBINED STB AND A.

TIVO ADS LAUNCHES ENHANCED U.S. TV VIEWERSHIP DATA OFFERING, UNIFYING STB AND ACR DATA IN A SINGLE FEED

 NEW DATA FROM THE PHASE 3 INDIGO OPEN-LABEL EXTENSION WILL INCLUDE THE LONGER-TERM FLARE PROTECTION AND SAFETY DATA OF OBEXELIMAB IN IGG4-RD 

ZENAS BIOPHARMA ANNOUNCES UPCOMING PRESENTATIONS OF OBEXELIMAB DATA IN IGG4-RELATED DISEASE AT THE IGG4WARD! 6TH INTERNATIONAL SYMPOSIUM ON IGG4-RELATED DISEASE AND ACR CONVERGENCE 2026

UNIONDALE, N.Y., SEPT. 16, 2026 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP.(NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED CASH DIVIDENDS ON ITS PREFERRED STOCK.

ACRES Commercial Realty

ACR

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR